06:10 AM EDT, 08/22/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to USD61 from USD49 implying 15.6x our 2025 EPADS, a discount to its historical forward P/E average of 25x-31x, justified in our view to reflect the increasing concern about its long-term competitive edge, but slightly above peer average of 13x to reflect NOVO's higher margin. We expect NOVO to maintain near-term leadership in the obesity market (alongside Eli Lilly), though rising competition poses long-term growth risk. Following a series of setbacks, including the second guidance cut that weighed on shares, NOVO offered some relief with U.S. approval of Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), the first GLP-1 class therapy cleared for this indication. While rival Eli Lilly is also pursuing Zepbound in MASH, the approval provides a welcome offset. Separately, Reuters reported that NOVO has frozen hiring in non-critical areas, a move that could help cushion margin.